Clinical trials: Non Alcoholic Fatty Liver
NASH
Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.
- Trial name
- NCT02923154
- Testing
- MT-3995
- Where
- 2 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Tanabe Pharma Corporation
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Non Alcoholic Fatty Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
The purpose of this study is to assess UDFF performance (compared to MRI)
- Trial name
- UDFF (NCT06080386)
- Testing
- UDFF
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Non-Alcoholic Fatty Liver Disease
Impact Of Choline in Patients With NAFLD
The study will be assessing the impact of choline supplementation in Non-alcoholic fatty liver disease patients using ultrasonography to show change in liver echogenicity, various laboratory tests as liver function, lipid profile…
- Trial name
- NCT05200156
- Testing
- Phosphatidyl Choline
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Type 2 Diabetes, Fatty Liver, Nonalcoholic
The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes
Moderate weight reduction by a moderately hypocaloric very-low-fat diet resulted in normalization of fasting hyperglycemia and reversal of hepatic insulin resistance in patients with poorly controlled type 2 diabetes.
- Trial name
- CH_DDZ (NCT04509245)
- Testing
- Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- German Diabetes Center
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
- Trial name
- LIRAINS (NCT01399645)
- Testing
- Liraglutide-metformin vs insulin-metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome
Exercise Study in Subjects With NAFLD
Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Exercise
- Trial name
- BestTreat (NCT03995056)
- Testing
- high-intensity aerobic interval training
- Where
- Finland
- Volunteers
- 49 people
- Sponsor
- University of Eastern Finland
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Noninvasive Biomarkers of Metabolic Liver Disease 1.1
NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to…
- Trial name
- NCT04828551
- Testing
- Ultrasound based shear wave speed and fat quantification methods, Blood collection, Physical measurements
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Chronic Liver Disease
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
- Trial name
- NCT06493799
- Testing
- LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Green Cross Wellbeing
NASH - Nonalcoholic Steatohepatitis
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
- Trial name
- NCT05022693
- Testing
- BIO89-100
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- 89bio, Inc.
Chronic Hepatitis C Virus, Non Alcoholic Fatty Liver Disease
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
Chronic hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD) are characterized by a spectrum of pathological conditions ranging from an early stage of inflammation and fibrosis up to more advanced…
- Trial name
- NCT02038387
- Testing
- normocaloric low cholesterol diet
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Roma La Sapienza
NAFLD
Hydroxytyrosol and Vitamin E in Pediatric NASH
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- NCT02842567
- Testing
- Hydroxytyrosol plus Vitamin E
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation
Effectiveness of Nutrition Education Program and Omega-3 Supplementation Among Non-alcoholic Fatty Liver Disease Patients
The aim of this clinical trial is to examine the impact of nutritional education and omega-3 supplementation in influencing body weight, liver enzyme levels, and lipid profiles in patients diagnosed with non-alcoholic fatty liver…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation, Nutrition Education Program
- Trial name
- NCT06627114
- Testing
- nutrition education program, Omega 3 fatty acids, control group
- Where
- Iraq
- Volunteers
- 159 people
- Sponsor
- Hawler Medical University
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Nonalcoholic Steatohepatitis
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
This clinical study is designed to evaluate the safety and immune modulatory effects of oral administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the metabolic syndrome.
- Trial name
- NCT01205087
- Testing
- OKT3
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- Hadassah Medical Organization
Nonalcoholic Steatohepatitis (NASH)
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
This study will evaluate the association of non-alcoholic fatty liver disease and coronary artery disease. All patients presenting for coronary angiogram will receive the following examination: Transient Elastography and…
- Trial name
- NCT01638832
- Testing
- Transient Elastography (FibroScan), Echosens, Paris, France, Controlled Attenuation Parameter (CAP), Echosens, Paris, France
- Where
- Germany
- Volunteers
- 572 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD in Flanders
In the Belgian adult population more than half, and numbers are still increasing, of the population is overweight or obese. These people are at risk to develop NAFLD. However, we lack epidemiological data in Belgium.
- Trial name
- NCT04647409
- Testing
- screening
- Where
- Belgium
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates
Nonalcoholic Liver disease (NAFLD) is known to be caused by deposition of fat in the liver. The impact of NAFLD on bariatric surgery is of great concern.
- Trial name
- NCT00887393
- Testing
- low carbohydrate diet, low-fat diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Michigan
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.